Healthcare company Humana announced the recent approval of a new financial institution target by the Science Based Targets initiative (SBTi). 

Humana’s Scope 3 asset class level target emphasizes its commitment to sustainable investment practices, according to a statement. The company commits to 67.3% of its listed equity and corporate bond portfolio by invested value, setting SBTi-validated targets by 2029 from a 2022 base year.

This complements the company’s existing targets covering the rest of its value chain, including a commitment to reduce absolute Scope 3 emissions from purchased goods and services, as well as upstream transportation and distribution, by 30% by 2032 from a 2022 base year. The newly approved target for Scope 3, Category 15 financed emissions refer to the indirect GHG emissions from investments and lending activities.

To achieve the financed emissions target, Humana has revised its investment policy to incorporate SBTi-aligned climate commitments. These proactive measures highlight Humana’s commitment to fostering healthier environments for its members, patients, employees, and communities, and aligns its financial influence with its operational impact.

Humana’s Scope 1 and 2 targets, which were approved in 2023, remain unchanged and continue to align with limiting global temperature rise. 

This milestone highlights Humana’s dedication to sustainability, reinforcing its commitment to improving health and well-being while aiming for significant emissions reductions across the company’s value chain.